Sanjivani Paranteral Ltd Q3 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/a75a1iop8oaffv8zlmwo28wj.pdf

Key Takeaways


SPL Infusion: The New Growth Engine

Ashwani Khemka: "That is the reason we are going slow on this thing so that by the end of November, December, we have a good product portfolio of around 20 to 23 products, which most of the competitors do not have."

Base Business: Injectables, Orals & the Mix Shift


Margins: Mix-Led Expansion, Utilization-Led Ambition


Regulatory & Compliance Edge

Srivardhan Khemka: "I'm happy to report that all our plants are compliant with the revised Schedule M, in which from our estimates in our country, there are only 20% to 30% of the plants who will actually comply."

Capital & Shareholding


Guidance & Commitments

CommitmentSpecificsTimeline
Base business FY26 revenueINR72–75 croresFY26 close
Base business FY27 revenue~INR90 croresFY27
SPL Infusion FY27 revenueINR60–65 croresFY27
SPL Infusion utilization40–50% (from 20–25% currently)FY27
SPL Infusion product portfolio20–23 productsBy Nov/Dec (calendar year)
SPL Infusion peak revenue>INR120–130 croresAt peak capacity (undated)
SPL Infusion peak EBITDA margin19–20%At peak capacity (undated)
Base business growth accelerationPotentially reaching 25%From Q2 or Q3 FY27
Base business long-term growth18–20% (higher with Africa approvals)FY27–FY28 and beyond
Base business EBITDA margin16–17%Sustaining range
SPL Infusion initial EBITDA margin17–18%Initial phase
FY27 base business capexINR4–4.5 croresFY27
PPP project updateDeferred to Q4 resultsQ4 FY26 call
Promoter shareholding increaseYear-on-year increase (subject to 5% cap)Ongoing

Key Metrics

MetricQ3 FY26
Standalone revenue₹20.9 cr, +20.2% YoY
Consolidated revenue₹22.1 cr, +27.1% YoY
Standalone EBITDA₹3.9 cr, +36% YoY
Consolidated EBITDA₹14.1 cr, +44.8% YoY
Standalone EBITDA margin18.4%, vs 16.2% in Q3 FY25
Consolidated EBITDA margin18.5%, vs 16.2% in Q3 FY25
Standalone PAT₹2.6 cr, +37.9% YoY
Consolidated PAT₹2.38 cr, +46.3% YoY
Consolidated PAT after non-controlling interest₹2.7 cr, +42.6% YoY
Injectable segment revenue₹11.7 cr, -9.7% YoY
Oral segment revenue₹8.6 cr, +153.3% YoY
Nutraceutical segment revenue₹0.56 cr
SPL Infusion (Pune) first-time revenue contribution₹1.2 cr
Export share of total revenue76.9%, core markets Middle East, Africa, Latin America
SPL Infusion current capacity utilization20% to 25%
FY27 base business revenue target~₹90 cr
FY27 SPL Infusion revenue target₹60 cr to ₹65 cr
SPL Infusion peak revenue potentialabove ₹120 cr to ₹130 cr
SPL Infusion peak EBITDA margin target19% to 20%
FY27 base business capex plan₹4 cr to ₹4.5 cr
Base business EBITDA margin trajectory (9M FY26)16% to 17%
Pune business early-stage EBITDA target17% to 18%, expected to rise with utilization